ClinicalTrials.gg
CompletedNCT01546649Updated Nov 26, 2015Results posted

A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer

A Phase 3 interventional study of TAP-144-SR(6M) and TAP-144-SR(3M) in Premenopausal Breast Cancer, sponsored by Takeda. Completed at 15 sites in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-11-26.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 266 studies in Breast Neoplasms with a site in Japan — 51 open to participants now, 113 under way, 56 of them phase 3. Breast Neoplasms · Japan.

Enrollment
153rd of 248
167 · median 281
Started
2012
with 9 others
Phase 3
112 of 266
18 open now
Registered
72nd of 266
by date

Among the 266 studies in Breast Neoplasms with a site in Japan, this one is the 153rd largest by enrollment of the 248 interventional ones that give a count, is one of 10 that started in 2012, is one of 112 in phase 3, and was the 72nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

51 of the 266 studies in Breast Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Breast Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

Hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) will be evaluated against TAP-144-SR(3M) in postoperative and hormone therapy-naïve patients with premenopausal breast cancer

03

Conditions studied

  • Premenopausal Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant has histopathologically-confirmed primary breast cancer in Japanese.
  2. The participant is aged 20 years or older when is obtained
  3. The participant has estrogen receptor (ER)-positive tumor cells and/or progesterone receptor (PgR)-positive primary tumor. And is negative.
  4. The participant has breast cancer in the clinical stages of T1-T3, N-any and M0 by TNM classification (the seventh edition, proposed by UICC in 2009). (No distant to lung, liver and bone should be confirmed on the image-based diagnosis at study enrollment. The image taken within 12 weeks prior to study enrollment is also available for the diagnosis.) The number of axillary lymph node metastasis is not limited.
  5. Any operative procedure for breast cancer is acceptable. In principle, after breast-conserving surgery, the participant will receive postoperative radiation to the conserving breast.
  6. chemotherapy and adjuvant chemotherapy prior to study enrollment are acceptable. (It is advisable the same kind of chemotherapy is performed at each site.)
  7. The participant has a history of regular menstrual periods within 12 weeks prior to study enrollment, or the participant has FSH of less than 40 mIU/mL and E2 of 10 pg/mL or more measured within 12 weeks prior to study enrollment. The participant has not had a chemical menopause (i.e., FSH of less than 40 mIU/mL and E2 of 10 pg/mL or more) within 12 weeks after completing adjuvant chemotherapy.
  8. The participant is in a condition to receive study drug and Tamoxifen (TAM) within 12 weeks after surgery or after adjuvant chemotherapy prior to study enrollment. Adjuvant chemotherapy prior to study is required to have been completed at the time of study enrollment.
  9. The participant has performance status of grades 0 or 1 at the time of study enrollment.
  10. The participant meets the following criteria of hepatic, renal and bone marrow functions on the laboratory test results at screening:

    • Hepatic function: (GOT) ≤ 3.0 times the (ULN) ALT (GPT) ≤ 3.0 times the ULN
    • Renal function: serum creatinine level \< 1.5 times the ULN
    • Bone marrow function : white blood cell count ≥ 3,000/mm3 count ≥ 100,000/μL ≥ 10.0g/dL
  11. The participant agrees to use a non-hormonal method of through the study period.

Exclusion criteria

Exclusion Criteria:

  1. The participant has received or adjuvant hormonal therapy for the latest breast cancer surgery.
  2. The participant has received bilateral oophorectomy and bilateral ovarian irradiation.
  3. The participant has inflammatory breast cancer or bilateral breast cancer.
  4. The participant has non-invasive ductal carcinoma.
  5. The participant has multiple primary cancers, or a history of carcinoma in other organs.
  6. The participant is pregnant or breast-feeding.
  7. The participant has a history of to synthetic LH-RH, LH-RH derivative, TAM, TAM analogue (antiestrogen) or any component of the study drug.
  8. The participant has a history of, or has been diagnosed with thromboembolism including myocardial infarction, cerebral infarction, venous thrombosis, and pulmonary embolism, or cardiac failure.
  9. Patients whose interval exceeded 460 msec on the 12-lead at screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    TAP-144-SR(6M)

    TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks.

    Drug: TAP-144-SR(6M)

  • Active comparator
    TAP-144-SR(3M)

    TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks.

    Drug: TAP-144-SR(3M)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=<30 pg/mL) From Week 4 Through Week 48

    Comparison of both the treatment groups was done by assessing the suppressive effect on serum E2 concentration maintained at menopausal level (=\<30pg/mL). Suppression rate was calculated as proportion of participants maintained at menopausal level.

    Time frame: Week 4 up to Week 48

Secondary outcomes

  1. Concentration of Serum E2

    The measure indicates serum E2 concentration at baseline and post-baseline time points.

    Time frame: Baseline, Hour (hr) 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673

  2. Concentration of Serum Luteinizing Hormone (LH)

    This measure indicates serum LH concentration at baseline and post-baseline time points. It was measured in milli-international units per milliliter (mIU/mL).

    Time frame: Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673

  3. Concentration of Follicle Stimulating Hormone (FSH)

    This measure indicates serum FSH concentration at baseline and post-baseline time points.

    Time frame: Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673

  4. Disease Free Survival (DFS) Rate at Week 96

    DFS is defined as time from randomization to earliest day of onset the events, recurrence \[including recurrence in the ipsilateral breast\], secondary cancer \[including breast cancer in the contralateral breast\] and death. DFS at Week 96 was defined as the percentage, calculated with Kaplan-Meier method, of participants did not experience any events at Week 96 since the randomization.

    Time frame: Week 96

  5. Distant Disease Free Survival (DDFS) Rate at Week 96

    DDFS is defined as time from randomization to earliest day of onset the events, distant recurrence, secondary cancer \[including breast cancer in the contralateral breast\] and death. DDFS at week 96 was defined as the percentage calculated with Kaplan-Meier method, of participants did not experience any events at week 96 since the randomization.

    Time frame: Week 96

  6. Serum Unchanged TAP-144 Level

    This measure indicates the unchanged TAP-144 level in serum.

    Time frame: Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309 and 337

  7. QT Interval Measured by 12-lead Electrocardiogram (ECG)

    12-lead electrocardiography measurement was performed in supine position after 5 minutes at rest. Each measurement was recorded continuously for 10 seconds at the recording speed of 25 millimeter/second (mm/second).

    Time frame: Baseline, Hour 1, 3, 6 on Day 1, Day 29, 85, 169 and 337

07

Results

Posted Nov 26, 2015

Participant flow

Participants took part in the study at 21 investigative sites in Japan from April 2012 to December 2014.

Participant flow — Overall Study
MilestoneTAP-144-SR (6M)TAP-144-SR (3M)
Started8384
Completed7575
Not completed89
Withdrew: Adverse event45
Withdrew: Protocol violation10
Withdrew: Lack of efficacy10
Withdrew: Recurrence11
Withdrew: Discovery of secondary cancer01
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryPercentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=<30 pg/mL) From Week 4 Through Week 48

Comparison of both the treatment groups was done by assessing the suppressive effect on serum E2 concentration maintained at menopausal level (=\<30pg/mL). Suppression rate was calculated as proportion of participants maintained at menopausal level.

Time frame:
Week 4 up to Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=<30 pg/mL) From Week 4 Through Week 48
percentage of participantsTAP-144-SR (6M)TAP-144-SR (3M)
Percentage of Participants With Suppressive Effect of Serum Estradiol (E2) to Menopausal Level (=<30 pg/mL) From Week 4 Through Week 4897.6 (91.565 to 99.707)96.4 (89.916 to 99.257)
SecondaryConcentration of Serum E2

The measure indicates serum E2 concentration at baseline and post-baseline time points.

Time frame:
Baseline, Hour (hr) 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673
Reported as:
Median · pg/mL
Concentration of Serum E2
pg/mLTAP-144-SR (6M)TAP-144-SR (3M)
Baseline [N=83;84]95 (0 to 652)99 (0 to 533)
Day1 (1hr) [N=82;84]94.5 (0 to 616)110.5 (0 to 518)
Day1 (3hr) [N=24;21]102.0 (0 to 602)64.0 (15 to 404)
Day1 (6hr) [N=24;21]153.5 (0 to 681)99.0 (16 to 533)
Day2 [N=83;84]146.0 (0 to 693)115.5 (0 to 333)
Day3 [N=83;84]100.0 (0 to 417)87.5 (0 to 311)
Day4 [N=83;84]108.0 (0 to 543)110.0 (0 to 453)
Week 1 (Day8) [N=83;84]56.0 (0 to 904)112.0 (0 to 981)
Week 2 (Day15) [N=83;84]13.0 (0 to 866)0.0 (0 to 1220)
Week 3 (Day22) [N=83;84]0.0 (0 to 196)0.0 (0 to 722)
Week 4 (Day29) [N=83;84]0.0 (0 to 14)0.0 (0 to 50)
Week 8 (Day57) [N=83;84]0.0 (0 to 12)0.0 (0 to 158)
Week 12 (Day85) [N=83;83]0.0 (0 to 12)0.0 (0 to 11)
Week 16 (Day113) [N=82;82]0.0 (0 to 69)0.0 (0 to 16)
Week 20 (Day141) [N=81;82]0.0 (0 to 15)0.0 (0 to 15)
Week 24 (Day169) [N=80;81]0.0 (0 to 27)0.0 (0 to 20)
Week 25 (Day176) [N=79;80]0.0 (0 to 18)0.0 (0 to 15)
Week 26 (Day183) [N=79;80]0.0 (0 to 14)0.0 (0 to 19)
Week 28 (Day197) [N=75;77]0.0 (0 to 14)0.0 (0 to 16)
Week 32 (Day225) [N=78;80]0.0 (0 to 17)0.0 (0 to 18)
Week 36 (Day253) [N=79;80]0.0 (0 to 18)0.0 (0 to 17)
Week 40 (Day281) [N=78;80]0.0 (0 to 184)0.0 (0 to 12)
Week 44 (Day309) [N=77;80]0.0 (0 to 16)0.0 (0 to 15)
Week 48 (Day337) [N=77;80]0.0 (0 to 15)0.0 (0 to 19)
Week 60 (Day421) [N=77;79]0.0 (0 to 25)0.0 (0 to 21)
Week 72 (Day505) [N=77;78]0.0 (0 to 14)0.0 (0 to 18)
Week 84 (Day589) [N=76;77]0.0 (0 to 15)0.0 (0 to 14)
Week 96 (Day673) [N=75;75]0.0 (0 to 12)0.0 (0 to 24)
SecondaryConcentration of Serum Luteinizing Hormone (LH)

This measure indicates serum LH concentration at baseline and post-baseline time points. It was measured in milli-international units per milliliter (mIU/mL).

Time frame:
Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673
Reported as:
Median · mIU/mL
Concentration of Serum Luteinizing Hormone (LH)
mIU/mLTAP-144-SR (6M)TAP-144-SR (3M)
Baseline [N=83;84]4.250 (0.69 to 65.33)4.490 (0.77 to 40.17)
Day1 (1hr) [N=82;84]27.730 (8.12 to 250.00)30.585 (2.78 to 207.30)
Day1 (3hr) [N=24;21]88.020 (24.64 to 250.00)63.260 (12.00 to 153.60)
Day1 (6hr) [N=24;21]64.750 (32.54 to 198.90)61.210 (12.68 to 106.10)
Day2 [N=83;84]14.990 (3.22 to 90.63)19.755 (1.84 to 154.30)
Day3 [N=83;84]7.310 (1.28 to 27.86)10.500 (1.73 to 59.52)
Day4 [N=83;84]5.830 (1.13 to 41.16)9.375 (1.63 to 56.11)
Week 1 (Day8) [N=83;84]3.190 (0.75 to 25.08)4.475 (1.18 to 29.68)
Week 2 (Day15) [N=83;84]2.460 (0.76 to 10.56)1.990 (0.75 to 9.65)
Week 3 (Day22) [N=83;84]1.020 (0.24 to 4.39)1.085 (0.38 to 5.35)
Week 4 (Day29) [N=83;84]0.540 (0.16 to 1.85)0.845 (0.33 to 2.73)
Week 8 (Day57) [N=83;84]0.270 (0.00 to 1.15)0.570 (0.00 to 5.17)
Week 12 (Day85) [N=83;83]0.220 (0.00 to 1.84)0.520 (0.00 to 2.70)
Week 16 (Day113) [N=82;82]0.245 (0.00 to 7.08)0.430 (0.00 to 1.42)
Week 20 (Day141) [N=81;82]0.240 (0.00 to 2.26)0.405 (0.00 to 2.93)
Week 24 (Day169) [N=80;81]0.290 (0.00 to 8.01)0.460 (0.11 to 2.96)
Week 25 (Day176) [N=79;80]0.450 (0.00 to 7.92)0.455 (0.15 to 1.47)
Week 26 (Day183) [N=79;80]0.410 (0.12 to 2.46)0.405 (0.14 to 1.70)
Week 28 (Day197) [N=75;77]0.270 (0.11 to 0.95)0.410 (0.11 to 1.68)
Week 32 (Day225) [N=78;80]0.280 (0.00 to 1.31)0.440 (0.14 to 2.45)
Week 36 (Day253) [N=79;80]0.250 (0.00 to 2.02)0.395 (0.11 to 2.01)
Week 40 (Day281) [N=78;80]0.240 (0.00 to 2.05)0.390 (0.12 to 1.75)
Week 44 (Day309) [N=77;80]0.250 (0.00 to 2.67)0.385 (0.00 to 2.14)
Week 48 (Day337) [N=77;80]0.250 (0.00 to 2.12)0.415 (0.11 to 1.30)
Week 60 (Day421) [N=77;79]0.250 (0.00 to 1.52)0.440 (0.00 to 2.57)
Week 72 (Day505) [N=77;78]0.260 (0.00 to 1.24)0.420 (0.00 to 1.91)
Week 84 (Day589) [N=76;77]0.230 (0.00 to 1.30)0.410 (0.00 to 1.34)
Week 96 (Day673) [N=75;75]0.210 (0.00 to 1.48)0.360 (0.00 to 1.63)
SecondaryConcentration of Follicle Stimulating Hormone (FSH)

This measure indicates serum FSH concentration at baseline and post-baseline time points.

Time frame:
Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309, 337, 421, 505, 589 and 673
Reported as:
Median · mIU/mL
Concentration of Follicle Stimulating Hormone (FSH)
mIU/mLTAP-144-SR (6M)TAP-144-SR (3M)
Baseline [N=83;84]5.070 (1.97 to 57.33)5.605 (2.03 to 66.13)
Day1 (1hr) [N=82;84]9.520 (4.01 to 102.42)10.000 (4.02 to 99.71)
Day1 (3hr) [N=24;21]23.325 (8.39 to 110.28)19.950 (10.06 to 74.66)
Day1 (6hr) [N=24;21]27.460 (11.19 to 147.78)25.340 (10.85 to 107.69)
Day2 [N=83;84]10.080 (2.78 to 93.70)12.515 (3.23 to 115.42)
Day3 [N=83;84]6.180 (2.86 to 45.56)6.780 (3.09 to 55.25)
Day4 [N=83;84]6.100 (2.84 to 37.79)5.585 (2.75 to 36.28)
Week 1 (Day8) [N=83;84]3.920 (0.99 to 14.09)3.035 (1.19 to 11.62)
Week 2 (Day15) [N=83;84]1.820 (0.58 to 7.49)1.705 (0.47 to 4.63)
Week 3 (Day22) [N=83;84]1.220 (0.49 to 3.22)1.570 (0.49 to 4.68)
Week 4 (Day29) [N=83;84]1.200 (0.39 to 2.48)2.015 (0.68 to 7.37)
Week 8 (Day57) [N=83;84]1.390 (0.36 to 5.15)2.345 (0.87 to 7.75)
Week 12 (Day85) [N=83;83]1.490 (0.37 to 5.72)2.240 (0.76 to 7.06)
Week 16 (Day113) [N=82;82]1.635 (0.59 to 11.04)1.830 (0.69 to 4.82)
Week 20 (Day141) [N=81;82]1.780 (0.53 to 7.28)1.905 (0.87 to 8.76)
Week 24 (Day169) [N=80;81]2.060 (0.42 to 6.24)2.000 (0.59 to 6.52)
Week 25 (Day176) [N=79;80]1.940 (0.71 to 5.22)1.600 (0.51 to 4.25)
Week 26 (Day183) [N=79;80]1.560 (0.53 to 3.40)1.700 (0.64 to 3.71)
Week 28 (Day197) [N=75;77]1.310 (0.52 to 2.81)1.690 (0.59 to 5.91)
Week 32 (Day225) [N=78;80]1.595 (0.52 to 4.81)1.980 (0.57 to 4.69)
Week 36 (Day253) [N=79;80]1.660 (0.73 to 6.12)2.035 (0.67 to 5.49)
Week 40 (Day281) [N=78;80]1.735 (0.75 to 4.09)1.710 (0.71 to 7.62)
Week 44 (Day309) [N=77;80]1.930 (0.72 to 5.01)1.825 (0.70 to 6.39)
Week 48 (Day337) [N=77;80]1.920 (0.69 to 8.37)1.885 (0.72 to 4.09)
Week 60 (Day421) [N=77;79]1.530 (0.74 to 4.71)1.910 (0.64 to 4.75)
Week 72 (Day505) [N=77;78]1.730 (0.92 to 5.89)1.920 (0.63 to 4.30)
Week 84 (Day589) [N=76;77]1.500 (0.77 to 3.23)1.840 (0.66 to 3.74)
Week 96 (Day673) [N=75;75]1.620 (0.76 to 4.57)1.740 (0.59 to 7.01)
SecondaryDisease Free Survival (DFS) Rate at Week 96

DFS is defined as time from randomization to earliest day of onset the events, recurrence \[including recurrence in the ipsilateral breast\], secondary cancer \[including breast cancer in the contralateral breast\] and death. DFS at Week 96 was defined as the percentage, calculated with Kaplan-Meier method, of participants did not experience any events at Week 96 since the randomization.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Disease Free Survival (DFS) Rate at Week 96
percentage of participantsTAP-144-SR (6M)TAP-144-SR (3M)
Disease Free Survival (DFS) Rate at Week 9697.397.5
SecondaryDistant Disease Free Survival (DDFS) Rate at Week 96

DDFS is defined as time from randomization to earliest day of onset the events, distant recurrence, secondary cancer \[including breast cancer in the contralateral breast\] and death. DDFS at week 96 was defined as the percentage calculated with Kaplan-Meier method, of participants did not experience any events at week 96 since the randomization.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Distant Disease Free Survival (DDFS) Rate at Week 96
percentage of participantsTAP-144-SR (6M)TAP-144-SR (3M)
Distant Disease Free Survival (DDFS) Rate at Week 9698.598.8
SecondarySerum Unchanged TAP-144 Level

This measure indicates the unchanged TAP-144 level in serum.

Time frame:
Baseline, Hour 1, 3, 6 on Day 1, Day 2, 3, 4, 8, 15, 22, 29, 57, 85, 113, 141, 169, 176, 183, 197, 225, 253, 281, 309 and 337
Reported as:
Mean · nanogram per deciliter (ng/dL)
Serum Unchanged TAP-144 Level
nanogram per deciliter (ng/dL)TAP-144-SR (6M)TAP-144-SR (3M)
Baseline [N=83;84]0.000 ± 0.00000.000 ± 0.0000
Day1 (1hr) [N=82;84]5.293 ± 1.068428.45 ± 9.7398
Day1 (3hr) [N=24;19]2.538 ± 0.4602320.27 ± 3.9535
Day1 (6hr) [N=24;21]1.039 ± 0.232648.037 ± 1.7408
Day2 [N=83;84]0.1401 ± 0.0661370.4749 ± 0.17801
Day3 [N=83;84]0.02889 ± 0.0261080.2492 ± 0.097054
Day4 [N=83;84]0.02380 ± 0.0226450.2273 ± 0.080794
Week 1 (Day8) [N=82;83]0.09115 ± 0.226370.1050 ± 0.049062
Week 2 (Day15) [N=82;84]0.3702 ± 0.251340.08867 ± 0.077142
Week 3 (Day22) [N=83;84]0.7285 ± 0.356390.06471 ± 0.092279
Week 4 (Day29) [N=83;83]0.3442 ± 0.198140.04971 ± 0.032917
Week 8 (Day57) [N=83;83]0.1146 ± 0.0530680.04744 ± 0.032379
Week 12 (Day85) [N=83;83]0.08051 ± 0.0418810.06028 ± 0.031104
Week 16 (Day113) [N=82;82]0.05775 ± 0.0370980.09347 ± 0.077284
Week 20 (Day141) [N=81;82]0.03941 ± 0.0370820.07165 ± 0.062739
Week 24 (Day169) [N=80;81]0.02931 ± 0.0197850.07634 ± 0.064118
Week 25 (Day176) [N=79;80]0.1128 ± 0.167510.1583 ± 0.089299
Week 26 (Day183) [N=79;80]0.3327 ± 0.364740.1109 ± 0.065133
Week 28 (Day197) [N=80;80]0.4687 ± 0.360830.08468 ± 0.040820
Week 32 (Day225) [N=78;80]0.1377 ± 0.0933400.06881 ± 0.037607
Week 36 (Day253) [N=79;80]0.08521 ± 0.0403240.06259 ± 0.036687
Week 40 (Day281) [N=79;80]0.06073 ± 0.0322320.08163 ± 0.031631
Week 44 (Day309) [N=77;80]0.4339 ± 0.0265520.06479 ± 0.028540
Week 48 (Day337) [N=77;80]0.02957 ± 0.0171470.06313 ± 0.032149
SecondaryQT Interval Measured by 12-lead Electrocardiogram (ECG)

12-lead electrocardiography measurement was performed in supine position after 5 minutes at rest. Each measurement was recorded continuously for 10 seconds at the recording speed of 25 millimeter/second (mm/second).

Time frame:
Baseline, Hour 1, 3, 6 on Day 1, Day 29, 85, 169 and 337
Reported as:
Mean · millisecond (msec)
QT Interval Measured by 12-lead Electrocardiogram (ECG)
millisecond (msec)TAP-144-SR (6M)TAP-144-SR (3M)
Baseline [N=83;84]421.5 ± 16.05420.9 ± 16.53
Day1 (1hr) [N=83;84]417.8 ± 15.37417.1 ± 17.83
Day1 (3hr) [N=24;21]416.8 ± 11.34423.7 ± 18.90
Day1 (6hr) [N=24;21]415.8 ± 18.68424.1 ± 13.76
Week 4 (Day29) [N=83;84]431.2 ± 19.30432.3 ± 16.90
Week 12 (Day85) [N=83;84]433.3 ± 19.44432.3 ± 20.01
Week 24 (Day169) [N=81;82]431.0 ± 21.22429.0 ± 20.28
Week 48 (Day337) [N=77;80]430.0 ± 17.31431.4 ± 18.89

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TAP-144-SR (6M)—6/83 (7.2%)82/83 (98.8%)
TAP-144-SR (3M)—7/84 (8.3%)82/84 (97.6%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventTAP-144-SR (6M)TAP-144-SR (3M)
Eyelid ptosisEye disorders1/830/84
Anal fistulaGastrointestinal disorders1/830/84
GastroenteritisInfections and infestations1/830/84
Infectious mononucleosisInfections and infestations1/830/84
Multiple sclerosisNervous system disorders1/830/84
VIIth nerve paralysisNervous system disorders1/830/84
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/831/84
CholelithiasisHepatobiliary disorders0/831/84
SinusitisInfections and infestations0/831/84
Occult blood positiveInvestigations0/831/84
Most frequent other events
Showing 10 of 44
Most frequent other events
EventTAP-144-SR (6M)TAP-144-SR (3M)
Hot flushVascular disorders43/8348/84
NasopharyngitisInfections and infestations47/8342/84
Radiation skin injuryInjury, poisoning and procedural complications31/8339/84
Injection site indurationGeneral disorders36/8333/84
White blood cell count decreasedInvestigations27/8319/84
Injection site painGeneral disorders24/8326/84
HeadacheNervous system disorders21/8319/84
ArthralgiaMusculoskeletal and connective tissue disorders18/8320/84
ConstipationGastrointestinal disorders13/832/84
MalaiseGeneral disorders13/8313/84

Baseline characteristics

Full analysis set (FAS) included all randomized participants who had received at least a single dose of study treatment.

Age, Continuous
Age, Continuous(years)TAP-144-SR (6M)TAP-144-SR (3M)Total
Mean44.2 ± 4.9044.0 ± 5.1844.1 ± 5.03
Age, Customized
Age, Customized(participants)TAP-144-SR (6M)TAP-144-SR (3M)Total
Less than (<) 40 years131225
Greater than equal to (>=) 40 to <45 years293059
>=45 years414283
Sex: Female, Male
Sex: Female, Male(Participants)TAP-144-SR (6M)TAP-144-SR (3M)Total
Female8384167
Male000
Height
Height(centimeter (cm))TAP-144-SR (6M)TAP-144-SR (3M)Total
Mean159.3 ± 5.11158.1 ± 5.00158.7 ± 5.08
Height, Customized
Height, Customized(participants)TAP-144-SR (6M)TAP-144-SR (3M)Total
<150 cm235
>=150 to <160 cm405393
>=160 cm412869
Weight
Weight(kilogram (kg))TAP-144-SR (6M)TAP-144-SR (3M)Total
Mean54.48 ± 7.67053.57 ± 7.49854.02 ± 7.574
Weight, Customized
Weight, Customized(participants)TAP-144-SR (6M)TAP-144-SR (3M)Total
<50 kg252954
>=50 to <60 kg404080
>=60 kg181533
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))TAP-144-SR (6M)TAP-144-SR (3M)Total
Mean21.50 ± 3.04221.45 ± 2.90221.48 ± 2.964

28 further baseline measures are reported on the registry.

08

Study locations

15 sites
  • Nagoya-shi, Aichi, Japan
  • Fukushima-shi, Fukushima, Japan
  • Maebashi-shi, Gunma, Japan
  • Ohta-shi, Gunma, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Isehara-shi, Kanagawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Kumamoto-shi, Kumamoto, Japan
  • Kyoto-shi, Kyoto, Japan
  • Nigata-shi, Nigata, Japan
  • Kurashiki-shi, Okayama, Japan
  • Osaka-shi, Osaka, Japan
  • Suita-shi, Osaka, Japan
  • Kita-adachi-gun, Saitama, Japan
  • Shinjuku-ku, Tokyo, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2012
First posted
Mar 7, 2012
Start
Apr 2012
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Nov 26, 2015
Last update
Nov 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01546649
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 7, 2012
Start date
Apr 2012
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Nov 26, 2015
Last update
Nov 26, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion